• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

COVID-19 vaccines and Multiple sclerosis – update

February 26, 2021
Recommend to a Colleague print
 

Updates the February 11 slide deck. Includes data on the immune response to SARS-CoV-2, efficacy data for the Oxford-AstraZeneca vaccine, and updates the vaccine recommendations from the Canadian Network of MS Clinics.

13 slides

Download slide deck

TOPICS: COVID-19, Library, MS
Recommend to a Colleague

Related Posts

  • Ocrelizumab use throughout the MS clinical course: highlights from ECTRIMS 2025
    October 15, 2025
  • Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025
    October 7, 2025
  • ECTRIMS 2025 HIGHLIGHTS – SATURDAY, SEPTEMBER 27, 2025
    September 27, 2025
  • ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025
    September 26, 2025
  • ECTRIMS 2025 slide resource
    September 25, 2025
Go back to home page

Browse by Topic

  • EPILEPSY (37)
  • ECTRIMS 2025 (7)
  • MS (426)
  • BIOMARKERS IN MS (60)
  • Library (18)
  • CLINICAL CASES IN MS (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025 posted on September 26, 2025
  • Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025 posted on October 7, 2025
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions